Further studies revealed that CAFs activate human epidermal growth factor receptor 3 (HER3) in tumor cells by secreting NRG1, and pharmacological blockade of the NRG1-HER3 axis can inhibit the development of PCa hormone resistance. The gene discussed is NRG1; the disease is neoplasm.